ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Codexis Sets Up Two Pharma Deals

by Ann M. Thayer
August 17, 2015 | APPEARED IN VOLUME 93, ISSUE 32

Codexis has licensed its enzyme engineering technology to Merck & Co., a collaborator of eight years. In return, Codexis will get $5 million up front and up to $13 million over 15 to 24 months as it transfers the technology to a Merck site. If Merck uses enzymes developed with the technology to produce drug ingredients, Codexis can receive up to $15 million per product. In July 2014, Codexis licensed its technology to GlaxoSmithKline for $25 million. Separately, for $1 million up front and R&D payments, Codexis will develop an enzyme for an undisclosed biotherapeutic firm to use in preclinical development.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment